ClinicalTrials.gg
RecruitingNCT01524211Updated Jun 15, 2026

Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms

An interventional study of Zenith® t-Branch and Terumo Arch Branch in Thoracoabdominal Aortic Aneurysm and Aortic Arch Aneurysm, sponsored by Baptist Health South Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Baptist Health South Florida · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2012; still recruiting 14 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
235
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Zenith t-Branch Study Cohort: The purpose of this study is to collect information on the Cook Zenith t-Branch endovascular stent-graft system and the Terumo Arch Branch for the treatment of aortic aneurysms.

Terumo Arch Branch Study Cohort: The purpose of this additional study arm to the current IDE clinical trial is to collect a priori information on the Terumo Arch Branch Endograft for the treatment of proximal thoracic aortic pathologies that cannot be treated with conventional thoracic endografts.

Read the detailed description

Study Update as of 3/31/2025; 186 subjects successfully have been implanted with the Zenith t-Branch Device and 1 subject has been implanted with the Arch Branch to date and recruitment is ongoing.

02

Conditions studied

  • Thoracoabdominal Aortic Aneurysm
  • Aortic Arch Aneurysm

Keywords

  • Aortic Aneurysms
03

In context

Aortic Aneurysm, Thoracoabdominal

63 studies on the registry are indexed under Aortic Aneurysm, Thoracoabdominal; 31 are open to participants now.

This study's planned enrollment of 235 is above the median of 80 across 41 interventional studies indexed under Aortic Aneurysm, Thoracoabdominal.

Browse Aortic Aneurysm, Thoracoabdominal studies →

Lead sponsor

Baptist Health South Florida is the lead sponsor of 52 studies on the registry; 18 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Zenith t-Branch Eligibility Criteria:

Inclusion Criteria

The patient must have one of the following:

  1. Degenerative, atherosclerotic thoracoabdominal, suprarenal and juxtarenal aortic aneurysms (fusiform or saccular):≥55mm in diameter in a male or ≥50mm in diameter in a female, or
  2. Thoracoabdominal aortic aneurysm with a history of growth ≥0.5 cm per year, or
  3. Penetrating ulcers: ≥20mm in depth or
  4. Chronic type B aortic dissections: ≥50mm total aortic diameter or
  5. Symptomatic pathology (aneurysm, ulcer or chronic dissection) of any size.

Additional criteria for LP material

  • Iliofemoral access vessels \<8mm or with significant atherosclerotic occlusive disease that would require an iliac conduit as determined by the Principle Investigator

Exclusion Criteria

General Criteria

  1. Life-expectancy less than 12 months
  2. Refusal to receive blood products
  3. Age \<18 years
  4. Pregnant or breastfeeding or planning on becoming pregnant within 60 months
  5. Unwilling to comply with the follow-up schedule
  6. Inability or refusal to give by subject and/or Legally Authorized Representative (LAR); should one be utilized

Medical Criteria

  1. Uncontrolled systemic infection
  2. Untreatable
  3. Uncontrollable anaphylaxis to iodinated contrast
  4. Known allergy(ies) to device materials

Anatomic Criteria

  1. Any pathology of mycotic origin
  2. Aortic fistulous communication with non-vascular structure (e.g. esophagus, bronchial)
  3. Inability to insert the Zenith® t-Branch device through iliofemoral approach
  4. Proximal and distal neck angle less than 90 degrees relative to the long axis of the aneurysm
  5. Proximal landing zone length \<25mm to allow secure fixation and seal
  6. Proximal landing zone diameter of \<24mm or >42mm
  7. Distal landing zone length \<25mm in the abdominal aorta or \<20mm in the iliac arteries
  8. Distal landing zone diameter of \<14mm or >30mm in the abdominal aorta, or \<7mm or >28mm in the iliac arteries

Terumo Arch Branch Eligibility Criteria

Inclusion Criteria

The subject must have one of the following:

  1. Degenerative, atherosclerotic aneurysm involving the ascending aorta, aortic arch or proximal descending aorta ≥55 mm in diameter or > 50 mm with a history of growth ≥5 mm in the last 6 months, or
  2. Penetrating ulcers: ≥20 mm in depth, or
  3. Chronic aortic dissections: ≥50mm total aortic diameter. AND Prohibitive or high-risk for standard open surgical repair, defined as having one or more of the following pre-existing conditions.

    1. Age >85 years old.
    2. Prior median sternotomy (for any reason).
    3. Prior open or endovascular thoracic aortic repair.
    4. Severe aortic calcification.
    5. Severe occlusive disease of one or more arch vessels.
    6. Moderate-severe ( \<80% predicted).
    7. Severe CKD (Stage 3 or greater, \<60 mL/min).
    8. LV dysfunction.
    9. Chronic or use.
    10. History of increased risk of bleeding.
    11. Neurocognitive deficits that may significantly impact postoperative rehabilitation.
    12. Musculoskeletal conditions that may significantly impact postoperative rehabilitation.

Exclusion Criteria

General Criteria

  1. \<1 year.
  2. Refusal to receive blood products.
  3. Age \<18 years.
  4. Pregnant, breastfeeding, or planning to become pregnant within 60 months.
  5. Unwilling to comply with the follow-up schedule.
  6. Inability or refusal to give informed consent by subject and/or Legally Authorized Representative (LAR); should one be utilized.
  7. Willingness to travel, if needed, to participate in a manufacturer-sponsored clinical trial at another institution.

Medical Criteria

  1. Pending cardiac surgery.
  2. Untreatable severe, symptomatic coronary or valvular disease.
  3. Prior mechanical aortic valve replacement (not bioprosthetic).
  4. History of TAVR (Transcatheter Aortic Valve Replacement)
  5. Severe, calcific aortic valvular stenosis.
  6. Uncontrolled systemic infection.
  7. Untreatable malignancy with \<1 year expected survival.
  8. Uncontrollable anaphylaxis to iodinated contrast.
  9. Known allergy(ies) to device materials. (i.e. polyester, nitinol).

Anatomic Criteria

  1. Any pathology of mycotic origin.
  2. Aortic fistulous communication with non-vascular structure (e.g. esophagus, bronchial).
  3. Acute (\<2 weeks) aortic dissection.
  4. Type A dissection.
  5. Symptomatic or ruptured pathology.
  6. Anatomy suitable for repair using commercially-available endograft.
  7. Inability to insert the Arch Branch endograft through an iliofemoral approach.
  8. Untreated, known extracranial carotid stenosis >80%.
  9. Ascending aortic angulation with radius of curvature \<15mm in the intended landing zone.
  10. Proximal aortic landing zone length \<25 mm.
  11. Proximal aortic landing zone diameter of >43mm or \<28 mm.
  12. Distal aortic landing zone diameter \<20 mm.
  13. Total length along the outer curve from the distal coronary to the proximal edge of the brachiocephalic trunk \<70mm.
  14. Target arch vessels:
  15. Distal branch landing zone dimensions: I. Brachiocephalic trunk (innominate artery, BCT): Diameter >24 mm or \<6 mm, length \<15 mm. ii. Common carotid artery: Diameter \<6 mm, length \<25mm. iii. Subclavian artery: Diameter \<6 mm, length \<25mm.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
235 participants (estimated)

Study arms

  • Experimental
    Single Treatment Arm-Zenith t-Branch Cohort

    Zenith t-Branch Cohort:Those subjects eligible for enrollment will receive endovascular treatment with the investigational Zenith t-Branch Endovascular Graft.

    Device: Zenith® t-Branch

  • Experimental
    Single Treatment Arm-Terumo Arch Branch Cohort

    Terumo Arch Branch Cohort:Those subjects eligible for enrollment will receive endovascular treatment with the investigational Terumo Arch Branch Endovascular Graft.

    Device: Terumo Arch Branch

Interventions

  • DeviceZenith® t-Branch

    The t-Branch Endovascular Graft (Zenith® t-Branch) is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for additional fixation of the device. The purpose of the branches is to allow uninterrupted blood flow to visceral vessels of the aorta. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents. Although the standard Zenith t-Branch has four branches, it is anticipated that a small number of custom-made three branch devices will be included in this study for those patients in whom one of the visceral vessels is chronically thrombosed.

  • DeviceTerumo Arch Branch

    The Arch Branch endograft is a custom-made endograft based on the Relay thoracic stent graft platform. The device is intended to land proximally in the ascending aorta just distal to the sinotubular junction, and distally either in the native thoracic aorta for focal arch pathologies, or more extensive pathologies either extended with another commercially available thoracic endograft or mated to a pre-existing thoracic endograft, which would serve as a distal landing zone. It is constructed of polyester graft material (same as those used for the Terumo Relay Plus or Pro) sewn to self-expanding nitinol stents with suture. The graft is fully stented to provide stability and the expansile force necessary to open the lumen of the graft during deployment. Additionally, the stents provide the necessary attachment and seal of the graft to the aortic wall.

06

What researchers measure

Primary outcomes

  1. Early Mortality & Stroke

    The primary aim of this study is to determine the rate of early mortality and stroke after branch endograft treatment.

    Time frame: 30 days post implant of the branch endografts

Secondary outcomes

  1. Rates of Neurologic Complications/Late Branch Vessel Patency

    The secondary aims of this study are to determine the rates of neurologic complications and late branch/target vessel patency, type I and III endoleaks and secondary interventions after branch endograft treatment. In those subjects enrolled in the t-Branch cohort we will evaluate the fractional/proportional/percent applicability/eligibility of the (standard, off-the-shelf) Zenith® t-Branch in all patients who present with thoracoabdominal aortic aneurysms.

    Time frame: Day 0-Day 30 (Early) Day 31-1825 (Late)

07

Study locations

1 of 1 sites recruiting
  • Baptist Health South Florida|Boca Raton Regional Hospital (BRRH)
    Boca Raton, Florida 33486, United States
    Recruiting
08

References and documents

Publications

  • Finnesgard EJ, Beck AW, Eagleton MJ, Farber MA, Gasper WJ, Lee WA, Oderich GS, Schneider DB, Sweet MP, Timaran CH, Simons JP, Schanzer A; United States Aortic Research Consortium. Severity of acute kidney injury is associated with decreased survival after fenestrated and branched endovascular aortic aneurysm repair. J Vasc Surg. 2023 Oct;78(4):892-901. doi: 10.1016/j.jvs.2023.05.034. Epub 2023 Jun 16. PubMed 37330702 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2012 (actual). Primary completion is estimated for Dec 2031, 239 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2012
First posted
Feb 1, 2012
StartActual
Jan 25, 2012
Primary completionEst.
Dec 2031
CompletionEst.
Jan 2032
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01524211
Lead sponsor
Baptist Health South Florida
Collaborators
William Cook Australia, Bolton Medical
Responsible party
Sponsor
First posted
Feb 1, 2012
Start date
Jan 25, 2012
Primary completion
Dec 2031 (estimated)
Completion
Jan 2032 (estimated)
Last update
Jun 15, 2026

Study contacts

Lisamarie Kernicky, RN;BSN;CCRC
Contact
lkernicky@brrh.com
561-955-5239
W. Anthony Lee, MD
principal investigator · Lynn Heart and Vascular Institute, Boca Raton Regional Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion